53 episodes

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

Medical Industry Feature ReachMD

    • Science

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

    Challenges in Identifying, Assessing, & Monitoring Excessive Daytime Sleepiness in Obstructive Sleep Apnea

    Challenges in Identifying, Assessing, & Monitoring Excessive Daytime Sleepiness in Obstructive Sleep Apnea

    Guest: Paul Doghramji, MD


    Excessive daytime sleepiness (EDS) in obstructive sleep apnea (OSA) is frequently underrecognized, as patients may not understand the extent of their sleepiness and EDS does not always correlate with other OSA symptoms. However, it’s important for physicians to identify EDS as it may lead to adverse consequences.
    Dr. Paul P. Doghramji, Senior Family Physician at Collegeville Family Practice and Medical Director of Health Services at Ursinus College, discusses identifying EDS and the vital role assessment tools like the Epworth Sleepiness Scale can have in practice.
    This promotional, non-CME program is intended for U.S. physicians treating OSA.
    © 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.
    US-SLE-2000467 Rev0920

    Pathophysiology of Obstructive Sleep Apnea & Its Role in Excessive Daytime Sleepiness

    Pathophysiology of Obstructive Sleep Apnea & Its Role in Excessive Daytime Sleepiness

    Guest: Richard K. Bogan, MD


    Emerging science can help us better understand the link between obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS). While many factors, such as insufficient sleep, medication, or comorbid disorders, can cause your patients with OSA to feel sleepy, chronic sleep disruption and chronic intermittent hypoxia associated with OSA may also contribute to EDS.
    Here to discuss the important physiologic changes to gray and white matter that may occur in OSA and lead to EDS is Dr. Richard K. Bogan, Associate Clinical Professor at the University of South Carolina School of Medicine and Chairman and Chief Medical Officer at SleepMed, Inc.
    This promotional, non-CME program is intended for U.S. physicians treating OSA.
    Dr. Bogan is a paid consultant of Jazz Pharmaceuticals, Inc.
    © 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.
    US-SLE-2000467 Rev0920

    Prevalence of Excessive Daytime Sleepiness in Obstructive Sleep Apnea

    Prevalence of Excessive Daytime Sleepiness in Obstructive Sleep Apnea

    Host: Richard K. Bogan, MD


    While positive airway pressure is the standard of care treatment for obstructive sleep apnea (OSA), it may not always be enough to address the excessive daytime sleepiness (EDS) that some patients experience. In fact, in one study, up to 34 percent of patients with OSA still reported EDS (Epworth Sleepiness Score ≥10) despite more than 5 hours of CPAP use a night.
    Here, Dr. Richard K. Bogan, Associate Clinical Professor at the University of South Carolina School of Medicine and Chairman and Chief Medical Officer at SleepMed, Inc., sheds light on the prevalence of EDS in OSA. Specifically, Dr. Bogan discusses key data that has raised important observations about how commonly EDS may persist even when patients adhere to CPAP therapy.
    This promotional, non-CME program is intended for U.S. physicians treating OSA.
    Dr. Bogan is a paid consultant of Jazz Pharmaceuticals, Inc.
    © 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.
    US-SLE-2000467 Rev0920

    Adverse Event Detection & Reporting: What Healthcare Providers Need to Know

    Adverse Event Detection & Reporting: What Healthcare Providers Need to Know

    Host: Matt Birnholz, MD

    Guest: Jessica Ailani, MD


    What should you do if a patient uses a prescribed medication and experiences an adverse event? Here to walk us through what clinicians need to keep in mind when detecting and reporting adverse events is Dr. Jessica Ailani, Vice Chair of Strategic Planning in Medstar Georgetown Department of Neurology at Medstar Georgetown University Hospital in Washington, DC.

    USA-334-83979

    When Were Oral PPAs Considered for PAH Patients in Common Clinical Scenarios?

    When Were Oral PPAs Considered for PAH Patients in Common Clinical Scenarios?

    Host: Jennifer Caudle, DO

    Guest: Victor F Tapson, MD


    Please see the full Prescribing Information here.
    This program is intended for US healthcare professionals only and is not certified for continuing medical education. Sponsored by Actelion Pharmaceuticals US, Inc., the marketer and distributor of UPTRAVI® (selexipag).
    Although there is currently no cure, the treatment of pulmonary arterial hypertension (PAH) has evolved substantially and its impact on patients varies based on clinical factors, including etiology, functional class, and hemodynamic parameters.

    Dr. Jennifer Caudle is joined by pulmonologist Dr. Victor Tapson, Professor of Medicine at Cedars-Sinai Medical Center, to discuss results from the Prostacyclin International Expert Panel consensus survey on common clinical scenarios in which they considered adding oral prostacyclin pathway agents in patients with PAH.

    ABOUT THE PROSTACYCLIN INTERNATIONAL EXPERT PANEL CONSENSUS OPINIONS
    The Prostacyclin International Expert Panel was not a consensus conference such as one held by a task force convened for the purpose of developing treatment guidelines. The Prostacyclin International Expert Panel opinion survey statements are not intended to be formal treatment guidelines or recommendations, and survey results presented here must be validated with rigorous prospective studies. The Prostacyclin International Expert Panel opinion survey statements cannot replace assessment and/or clinical decision-making by a ...

    Clinical Trial Data Evaluating a Treatment for Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE) in Patients With Active Cancer

    Clinical Trial Data Evaluating a Treatment for Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE) in Patients With Active Cancer

    Host: Jennifer Caudle, DO

    Guest: Steven Fein, MD


    Here to delve into venous thromboembolism (VTE) clinical trial data on XARELTO®, a treatment option approved for deep vein thrombosis (DVT) and pulmonary embolism (PE), is Dr Steven Fein. He will highlight the EINSTEIN clinical trials, a subgroup analysis, and the results of a randomized, open-label pilot trial for the treatment of DVT and/or PE in patients with active cancer.
    This promotional educational activity is brought to you by Janssen Pharmaceuticals, Inc., and is not certified for continuing medical education. The consultant is a paid speaker for Janssen Pharmaceuticals, Inc. The speaker is presenting on behalf of Janssen and must present information in compliance with FDA requirements applicable to Janssen.
    ©Janssen Pharmaceuticals, Inc. 2020 August 2020 cp-145201v1

Top Podcasts In Science

Listeners Also Subscribed To

More by ReachMD